Association of Plasma Myeloperoxidase with Inflammation and Diabetic status in HFpEF

Sibille Lejeune1, Audrey Ginion1, Nassiba Menghoum1

  • 1Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St. Luc and Pôle de Recherche Cardiovasculaire (CARD), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, 1200 Brussels, Belgium.

Abstract

Insights

Heart failure with preserved ejection fraction (HFpEF) patients exhibit elevated myeloperoxidase (MPO) levels, linked to inflammation and oxidative stress. High MPO correlates with specific clinical factors but not vascular stiffness in HFpEF.

Area of Science:

  • Cardiovascular Medicine
  • Biomarkers
  • Inflammation and Oxidative Stress

Background:

  • Inflammation and oxidative stress are implicated in heart failure with preserved ejection fraction (HFpEF) pathophysiology.
  • Myeloperoxidase (MPO) bridges oxidative stress and inflammation, presenting a potential therapeutic target.
  • Endothelial dysfunction is a key feature in HFpEF development.

Purpose of the Study:

  • To compare MPO levels between HFpEF patients and older controls.
  • To identify clinical characteristics associated with elevated MPO levels in HFpEF.
  • To evaluate the relationship between MPO levels and vascular function in HFpEF.

Main Methods:

  • Observational cohort study including 55 HFpEF patients and 18 controls.
  • Assessment of MPO levels using ELISA.
  • Evaluation of vascular function via effective arterial elastance (Ea) and peripheral arterial tonometry (EndoPAT).

Main Results:

  • HFpEF patients showed significantly higher MPO levels compared to controls (p=0.026).
  • MPO levels correlated with inflammation markers (CRP, neutrophil-to-lymphocyte ratio) and indicators of diastolic dysfunction (NT-proBNP, E/e').
  • Higher MPO levels in HFpEF were associated with male sex and diabetes, but not with reduced endothelial function or increased vascular stiffness.

Conclusions:

  • Elevated MPO levels in HFpEF reflect leukocyte activation and oxidative stress.
  • High MPO is linked to male sex, diabetes, and diastolic dysfunction in HFpEF.
  • The study did not demonstrate a link between MPO-related oxidative stress and vascular stiffness in this cohort.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.